Activation of the peroxisome pathway implies that Lira promotes peroxisomal β-oxidation via PPARα, improves hepatic function, and supports its therapeutic role in MASLD [40]. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.